Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.3 · PDF-Seite 10
HOS-131792 · Präparat HOS-097138
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 8cc0fe29768569a55e0703c8413d5a145077448bca5f7426ab9084406d167fa6 · Zeichen 0–91 im Abschnitt
Gegenanzeigen · Keytruda
KEYTRUDA 395 mg solution for injection KEYTRUDA 790 mg solution for injection · Abschnitt 4.3 · PDF-Seite 169
HOS-131840 · Präparat HOS-097138
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 8cc0fe29768569a55e0703c8413d5a145077448bca5f7426ab9084406d167fa6 · Zeichen 0–91 im Abschnitt
Wechselwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 15
HOS-131793 · Präparat HOS-097138
No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab. Since
pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug
interactions are expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 79aa6cb6c06fe657a87766a758627b17c7fd06c3860e8868eed21bed8a7d73ad · Zeichen 0–212 im Abschnitt
Wechselwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 15
HOS-131794 · Präparat HOS-097138
The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be
avoided because of their potential interference with the pharmacodynamic activity and efficacy of
pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after
starting pembrolizumab to treat immune-mediated adverse reactions (see section 4.4). Corticosteroids
can also be used as premedication, when pembrolizumab is used in combination with chemotherapy,
as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 33e873ecc0e8e816826559577c4ffb70556d8a30e6ec96bad532f570fa77c6c9 · Zeichen 214–787 im Abschnitt
Wechselwirkungen · Keytruda
KEYTRUDA 395 mg solution for injection KEYTRUDA 790 mg solution for injection · Abschnitt 4.5 · PDF-Seite 174
HOS-131841 · Präparat HOS-097138
No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab. Since
pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug
interactions are expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 79aa6cb6c06fe657a87766a758627b17c7fd06c3860e8868eed21bed8a7d73ad · Zeichen 0–212 im Abschnitt
Wechselwirkungen · Keytruda
KEYTRUDA 395 mg solution for injection KEYTRUDA 790 mg solution for injection · Abschnitt 4.5 · PDF-Seite 174
HOS-131842 · Präparat HOS-097138
The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be
avoided because of their potential interference with the pharmacodynamic activity and efficacy of
pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after
starting pembrolizumab to treat immune-mediated adverse reactions (see section 4.4). Corticosteroids
can also be used as premedication, when pembrolizumab is used in combination with chemotherapy,
as antiemetic prophylaxis and/or to alleviate chemotherapy-related adverse reactions.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 33e873ecc0e8e816826559577c4ffb70556d8a30e6ec96bad532f570fa77c6c9 · Zeichen 214–787 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-131795 · Präparat HOS-097138
Summary of the safety profile
Pembrolizumab is most commonly associated with immune-mediated adverse reactions. Most of
these, including severe reactions, resolved following initiation of appropriate medical therapy or
withdrawal of pembrolizumab (see “Description of selected adverse reactions” below). The
frequencies included below and in Table 2 are based on all reported adverse drug reactions, regardless
of the investigator assessment of causality.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 6fce06a283217e1de58620b6cd6d4518b2997129df6084da6ab5855ffb51f8a2 · Zeichen 0–455 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-131796 · Präparat HOS-097138
Pembrolizumab in monotherapy (see section 4.2)
The safety of pembrolizumab as monotherapy has been evaluated in 7 631 patients across tumour
types and across four doses (2 mg/kg bw every 3 weeks, 200 mg every 3 weeks, or 10 mg/kg bw every
2 or 3 weeks) in clinical studies. In this patient population, the median observation time was
8.5 months (range: 1 day to 39 months) and the most frequent adverse reactions with pembrolizumab
were fatigue (31%), diarrhoea (22%), and nausea (20%). The majority of adverse reactions reported
for monotherapy were of Grades 1 or 2 severity. The most serious adverse reactions were
immune-mediated adverse reactions and severe infusion-related reactions (see section 4.4). The
incidences of immune-mediated adverse reactions were 37% all Grades and 9% for Grades 3-5 for
pembrolizumab monotherapy in the adjuvant setting and 25% all Grades and 6% for Grades 3-5 in the
metastatic setting. No new immune-mediated adverse reactions were identified in the adjuvant setting.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage dda1937bde4d8c6e0083a64c28d0e00eb8567b769f18bbc84f211d5e7789dbd4 · Zeichen 457–1463 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-131797 · Präparat HOS-097138
Pembrolizumab in combination with chemotherapy, radiation therapy (RT) or chemoradiotherapy
(CRT) (see section 4.2)
When pembrolizumab is administered in combination, refer to the SmPC for the respective
combination therapy components prior to initiation of treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 3e55ec485381d46f87a2c54a2c4350ba0b1b2da363215471a30390176885e216 · Zeichen 1465–1733 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 16
HOS-131798 · Präparat HOS-097138
The safety of pembrolizumab in combination with chemotherapy, RT or CRT has been evaluated in
7 015 patients across tumour types receiving 200 mg, 2 mg/kg bw or 10 mg/kg bw pembrolizumab
every 3 weeks or 400 mg pembrolizumab every 6 weeks, in clinical studies. In this patient population,
the most frequent adverse reactions were anaemia (51%), nausea (50%), fatigue (36%),
diarrhoea (35%), constipation (32%), vomiting (27%), and decreased appetite (26%). Incidences of
Grades 3-5 adverse reactions in patients with NSCLC were 69% for pembrolizumab combination
therapy and 61% for chemotherapy alone, in patients with HNSCC were 80% for pembrolizumab
combination therapy (chemotherapy or RT with or without chemotherapy), and 79% for chemotherapy
plus cetuximab or RT with or without chemotherapy, in patients with oesophageal carcinoma were
86% for pembrolizumab combination therapy and 83% for chemotherapy alone, in patients with
TNBC were 80% for pembrolizumab combination therapy and 77% for chemotherapy alone, in
patients with cervical cancer were 77% for pembrolizumab combination therapy (chemotherapy with
or without bevacizumab or in combination with CRT) and 71% for chemotherapy with or without
bevacizumab or CRT alone, in patients with gastric cancer were 74% for pembrolizumab combination
therapy (chemotherapy with or without trastuzumab) and 68% for chemotherapy with or without
trastuzumab, in patients with biliary tract carcinoma were 85% for pembrolizumab combination
therapy and 84% for chemotherapy alone, in patients with EC were 59% for pembrolizumab
combination therapy and 46% for chemotherapy alone, in patients with malignant pleural
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 0ccc8cc736ba0ac89c1d69b6fde9e85bc6279d7952581c3a063eb28f627c1409 · Zeichen 1735–3399 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 16–17
HOS-131799 · Präparat HOS-097138
16
mesothelioma were 44% for pembrolizumab combination therapy and 30% for chemotherapy alone
and in patients with ovarian cancer were 83% for pembrolizumab combination therapy (chemotherapy
with or without bevacizumab) and 71% for chemotherapy with or without bevacizumab.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage be12404c02178554830b9c420376a8466afe24efcda4b5c9005cfb40535e8785 · Zeichen 3450–3724 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-131800 · Präparat HOS-097138
Pembrolizumab in combination with tyrosine kinase inhibitor (TKI) (see section 4.2)
When pembrolizumab is administered in combination with axitinib or lenvatinib, refer to the SmPC
for axitinib or lenvatinib prior to initiation of treatment. For additional lenvatinib safety information
related to advanced RCC see the SmPC for Kisplyx and for advanced EC see the SmPC for Lenvima.
For additional axitinib safety information for elevated liver enzymes see also section 4.4.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 6bcd7a90f63b7c21cd6420a4d05eccb913c2e326523c096b8a8e1e66593ab7ec · Zeichen 3726–4199 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-131801 · Präparat HOS-097138
The safety of pembrolizumab in combination with axitinib or lenvatinib in advanced RCC, and in
combination with lenvatinib in advanced EC has been evaluated in a total of 1 456 patients with
advanced RCC or advanced EC receiving 200 mg pembrolizumab every 3 weeks with either axitinib
5 mg twice daily or lenvatinib 20 mg once daily in clinical studies, as appropriate. In these patient
populations, the most frequent adverse reactions were diarrhoea (58%), hypertension (54%),
hypothyroidism (46%), fatigue (41%), decreased appetite (40%), nausea (40%), arthralgia (30%),
vomiting (28%), weight decreased (28%), dysphonia (28%), abdominal pain (28%), proteinuria (27%),
palmar-plantar erythrodysaesthesia syndrome (26%), rash (26%), stomatitis (25%),
constipation (25%), musculoskeletal pain (23%), headache (23%) and cough (21%). Grades 3-5
adverse reactions in patients with RCC were 80% for pembrolizumab in combination with either
axitinib or lenvatinib and 71% for sunitinib alone. In patients with EC, Grades 3-5 adverse reactions
were 89% for pembrolizumab in combination with lenvatinib and 73% for chemotherapy alone.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage ccc47dd5eb2704f3c07bbb8a945844d8876e1c3f30f8639a8395363e6b6163a9 · Zeichen 4201–5328 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-131802 · Präparat HOS-097138
Tabulated summary of adverse reactions
Adverse reactions observed in clinical studies of pembrolizumab as monotherapy or in combination
with chemotherapy, RT or CRT or other anti-tumour medicines or reported from post-marketing use
of pembrolizumab are listed in Table 2. These reactions are presented by system organ class and by
frequency. Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10);
uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); very rare (< 1/10 000); and not
known (cannot be estimated from the available data). Within each frequency grouping, adverse
reactions are presented in the order of decreasing seriousness. Adverse reactions known to occur with
pembrolizumab or combination therapy components given alone may occur during treatment with
these medicinal products in combination, even if these reactions were not reported in clinical studies
with combination therapy.
For additional safety information when pembrolizumab is administered in combination, refer to the
SmPC for the respective combination therapy components.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage a0a6bea196f43883d0e5f0f9b1846dd9241ea72e2d19bbcfc2e40f58738f6bc2 · Zeichen 5330–6416 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-131803 · Präparat HOS-097138
Table 2: Adverse reactions in patients treated with pembrolizumab†
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 5d3e86a9287f7642ca475b12efae8947272a69f30b97aaa83e5cafd6d6c2fbdd · Zeichen 6418–6484 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17
HOS-131804 · Präparat HOS-097138
MedDRA SOC Monotherapy In combination with In combination with
and frequency chemotherapy, axitinib or lenvatinib
category radiation therapy or
chemoradiotherapy
Infections and infestations
Very common urinary tract infection
Common pneumonia pneumonia pneumonia
Blood and lymphatic system disorders
Very common anaemia anaemia, neutropenia, anaemia
thrombocytopenia
Common thrombocytopenia, febrile neutropenia, neutropenia,
neutropenia, leukopenia, lymphopenia thrombocytopenia,
lymphopenia lymphopenia,
leukopenia
Uncommon leukopenia, immune haemolytic anaemia⁎, eosinophilia
thrombocytopenia, eosinophilia
eosinophilia
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 05fa7f6e6efde73fe03145a20d81cf697f096745eb98d20833afd24f39608831 · Zeichen 6487–7783 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 17–18
HOS-131805 · Präparat HOS-097138
17
MedDRA SOC Monotherapy In combination with In combination with
and frequency chemotherapy, axitinib or lenvatinib
category radiation therapy or
chemoradiotherapy
Rare haemolytic immune
anaemia⁎, thrombocytopenia
haemophagocytic
lymphohistiocytosis,
pure red cell aplasia
Immune system disorders
Common infusion-related infusion-related reaction⁎ infusion-related
reaction⁎ reaction⁎
Uncommon sarcoidosis⁎
Rare sarcoidosis
Not known solid organ
transplant rejection
Endocrine disorders
Very common hypothyroidism⁎ hypothyroidism⁎ hypothyroidism
Common hyperthyroidism adrenal insufficiency⁎, adrenal insufficiency⁎,
hyperthyroidism⁎, hyperthyroidism,
thyroiditis⁎ thyroiditis⁎
Uncommon adrenal hypophysitis⁎ hypophysitis⁎
insufficiency⁎,
hypophysitis⁎,
thyroiditis⁎
Rare hypoparathyroidism hypoparathyroidism hypoparathyroidism
Metabolism and nutrition disorders
Very common decreased appetite hypokalaemia, decreased decreased appetite
appetite
Common hyponatraemia, hyponatraemia, hyponatraemia,
hypokalaemia, hypocalcaemia hypokalaemia,
hypocalcaemia hypocalcaemia
Uncommon type 1 diabetes type 1 diabetes mellitus⁎ type 1 diabetes
mellitus⁎ mellitus⁎
Psychiatric disorders
Very common insomnia
Common insomnia insomnia
Nervous system disorders
Very common headache neuropathy peripheral, headache, dysgeusia
headache
Common dizziness, dizziness, dysgeusia dizziness, neuropathy
neuropathy peripheral, lethargy
peripheral, lethargy,
dysgeusia
Uncommon myasthenic encephalitis⁎, lethargy myasthenic
syndrome⁎¶, epilepsy syndrome⁎¶,
encephalitis⁎
Rare Guillain-Barré myasthenic syndrome⁎¶, optic neuritis
syndrome⁎, Guillain-Barré
encephalitis⁎, syndrome⁎, myelitis,
myelitis⁎, optic optic neuritis, epilepsy,
neuritis, meningitis meningitis (aseptic)
(aseptic)⁎
Eye disorders
Common dry eye dry eye dry eye
Uncommon uveitis⁎ uveitis⁎ uveitis⁎
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 55d657121fac6d5def9e9d0f2d9639cc93046a87803d539f1292d1095c20dfb6 · Zeichen 7837–11462 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 18–19
HOS-131806 · Präparat HOS-097138
18
MedDRA SOC Monotherapy In combination with In combination with
and frequency chemotherapy, axitinib or lenvatinib
category radiation therapy or
chemoradiotherapy
Rare Vogt-Koyanagi-Har Vogt-Koyanagi-Harad
ada syndrome a syndrome
Cardiac disorders
Common cardiac arrhythmia‡ cardiac arrhythmia‡ cardiac arrhythmia‡
(including atrial (including atrial (including atrial
fibrillation) fibrillation) fibrillation)
Uncommon myocarditis¶, myocarditis⁎¶, myocarditis¶,
pericarditis⁎, pericarditis⁎, pericardial pericardial effusion
pericardial effusion effusion
Vascular disorders
Very common hypertension
Common hypertension hypertension
Uncommon vasculitis⁎ vasculitis⁎
Rare vasculitis⁎
Respiratory, thoracic and mediastinal disorders
Very common dyspnoea, cough dyspnoea, cough dyspnoea, cough
Common pneumonitis⁎ pneumonitis⁎ pneumonitis⁎
Gastrointestinal disorders
Very common diarrhoea, diarrhoea, nausea, diarrhoea, abdominal
abdominal pain⁎, vomiting, abdominal pain⁎, nausea,
nausea, vomiting, pain⁎, constipation vomiting, constipation
constipation
Common colitis⁎, dry mouth colitis⁎, gastritis⁎, dry colitis⁎, pancreatitis⁎,
mouth gastritis⁎, dry mouth
Uncommon pancreatitis⁎, pancreatitis⁎, gastrointestinal
gastritis ,
⁎
gastrointestinal ulceration⁎
gastrointestinal ulceration⁎
ulceration ⁎
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 310c57cb07e8624619ca99566cc9be7e2f1109ea68053ca4e1f5080e32e77d0e · Zeichen 11511–13941 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 19
HOS-131807 · Präparat HOS-097138
Rare pancreatic exocrine pancreatic exocrine small intestinal
insufficiency, small insufficiency, small perforation
intestinal intestinal perforation,
perforation, coeliac coeliac disease
disease
Not known pancreatic exocrine
insufficiency, coeliac
disease
Hepatobiliary disorders
Common hepatitis⁎ hepatitis⁎ hepatitis⁎
Rare cholangitis cholangitis sclerosing⁎
sclerosing
Skin and subcutaneous tissue disorders
Very common pruritus⁎, rash⁎ alopecia, pruritus⁎, rash⁎ rash⁎, pruritus⁎
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage bd1a5f0ac91a7904d508a70665c1731ea6d4d72baa5bf4a00bfbc38d7e9527e5 · Zeichen 13943–14894 im Abschnitt
Nebenwirkungen · Keytruda
KEYTRUDA 25 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 19
HOS-131808 · Präparat HOS-097138
Common severe skin severe skin reactions⁎, severe skin reactions⁎,
reactions⁎, erythema, dermatitis, erythema, dry dermatitis, dry skin,
dermatitis, dry skin, skin, dermatitis erythema, dermatitis
vitiligo⁎, eczema, acneiform, eczema acneiform, alopecia
alopecia, dermatitis
acneiform
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-01T16:10:00Z · SHA-256 e087d75948ee6d7e0436cc4d9426ed91824e992a89f4481a4ea0ddb3e3ee3588 · Passage 167cdb2a270aa6eeba3ff1818d231e5db4c2ad442779cb287b9fe095f61bc09c · Zeichen 14896–15357 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.